Online inquiry

IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2764MR)

This product GTTS-WQ2764MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF11 gene. The antibody can be applied in Multiple myeloma (MM), Osteoporosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003701.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8600
UniProt ID O14788
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2764MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2822MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ1109MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ6086MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ1773MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ13101MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ7605MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ14053MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW